Long-term management of cirrhosis centers on treating the underlying etiology, preventing and managing complications, and optimizing supportive care.
👉 General Principles of Long-Term Management
Treating the underlying cause is essential: antiviral therapy for hepatitis B or C, alcohol cessation for alcohol-related liver disease, and weight loss for nonalcoholic fatty liver disease can slow or reverse disease progression.
Lifestyle modifications include abstinence from alcohol, avoidance of NSAIDs, and optimizing nutrition (35 kcal/kg/day, 1.2–1.5 g/kg protein), with vitamin and zinc supplementation as needed.
Immunizations against hepatitis A and B, pneumococcal pneumonia, and influenza are recommended.
Surveillance for hepatocellular carcinoma (HCC) with ultrasound ± alpha-fetoprotein every 6 months, and for varices with esophagogastroduodenoscopy (EGD) at diagnosis and every 1–2 years thereafter, is standard.
👉 Portal Hypertension and Variceal Bleeding
Nonselective β-blockers are first-line for primary and secondary prophylaxis of variceal bleeding. Typical starting doses are propranolol 20–40 mg twice daily, nadolol 20–40 mg once daily, or carvedilol 6.25–12.5 mg once daily, titrated to achieve a resting heart rate of 55–60 bpm or the maximum tolerated dose.
If β-blockers are contraindicated or not tolerated, endoscopic variceal ligation is indicated.
For high-risk acute variceal hemorrhage, pre-emptive transjugular intrahepatic portosystemic shunt (TIPS) is considered.
👉 Ascites and Spontaneous Bacterial Peritonitis (SBP)
Sodium restriction to <2 g/day is recommended.
Diuretic therapy typically starts with spironolactone 100 mg plus furosemide 40 mg daily, maintaining a 100:40 mg ratio and titrating as needed to control ascites while avoiding electrolyte disturbances.
SBP prophylaxis is indicated for high-risk patients (e.g., prior SBP, low ascitic protein): ciprofloxacin 500 mg daily or trimethoprim-sulfamethoxazole (TMP-SMX) double-strength tablet daily.
Long-term albumin administration is under investigation for uncomplicated ascites.
👉 Hepatic Encephalopathy
Lactulose is first-line: 20–30 g (30–45 mL) orally every 1–2 hours until a bowel movement, then titrated to maintain 2–3 soft stools per day.
Rifaximin 550 mg twice daily is used for secondary prophylaxis.
👉 Hepatorenal Syndrome
Management includes IV albumin (1 g/kg on day 1, then 20–40 g/day) plus a vasoconstrictor: terlipressin (1 mg IV every 6 hours, titrated as needed) or norepinephrine (0.5–3 mg/hour).
👉 Other Complications and Supportive Care
For pruritus, cholestyramine 4–16 g/day is first-line; naltrexone may be used for refractory cases.
Muscle cramps may be treated with taurine 1000 mg twice daily.
Sleep disturbance can be managed with hydroxyzine 25 mg nightly, but caution is warranted due to the risk of precipitating encephalopathy.
Statins are safe in compensated cirrhosis at low doses and may have beneficial effects on fibrosis and outcomes.
Referral for liver transplantation should be considered in patients with decompensation or HCC.
Emerging therapies such as L-ornithine L-aspartate for hepatic encephalopathy and long-term albumin for ascites are under investigation and not yet standard of care. TIPS is increasingly considered earlier in refractory ascites and for high-risk variceal bleeding.
🌟 All management should be individualized, with close monitoring for adverse effects and complications.
👉 General Principles of Long-Term Management
Treating the underlying cause is essential: antiviral therapy for hepatitis B or C, alcohol cessation for alcohol-related liver disease, and weight loss for nonalcoholic fatty liver disease can slow or reverse disease progression.
Lifestyle modifications include abstinence from alcohol, avoidance of NSAIDs, and optimizing nutrition (35 kcal/kg/day, 1.2–1.5 g/kg protein), with vitamin and zinc supplementation as needed.
Immunizations against hepatitis A and B, pneumococcal pneumonia, and influenza are recommended.
Surveillance for hepatocellular carcinoma (HCC) with ultrasound ± alpha-fetoprotein every 6 months, and for varices with esophagogastroduodenoscopy (EGD) at diagnosis and every 1–2 years thereafter, is standard.
👉 Portal Hypertension and Variceal Bleeding
Nonselective β-blockers are first-line for primary and secondary prophylaxis of variceal bleeding. Typical starting doses are propranolol 20–40 mg twice daily, nadolol 20–40 mg once daily, or carvedilol 6.25–12.5 mg once daily, titrated to achieve a resting heart rate of 55–60 bpm or the maximum tolerated dose.
If β-blockers are contraindicated or not tolerated, endoscopic variceal ligation is indicated.
For high-risk acute variceal hemorrhage, pre-emptive transjugular intrahepatic portosystemic shunt (TIPS) is considered.
👉 Ascites and Spontaneous Bacterial Peritonitis (SBP)
Sodium restriction to <2 g/day is recommended.
Diuretic therapy typically starts with spironolactone 100 mg plus furosemide 40 mg daily, maintaining a 100:40 mg ratio and titrating as needed to control ascites while avoiding electrolyte disturbances.
SBP prophylaxis is indicated for high-risk patients (e.g., prior SBP, low ascitic protein): ciprofloxacin 500 mg daily or trimethoprim-sulfamethoxazole (TMP-SMX) double-strength tablet daily.
Long-term albumin administration is under investigation for uncomplicated ascites.
👉 Hepatic Encephalopathy
Lactulose is first-line: 20–30 g (30–45 mL) orally every 1–2 hours until a bowel movement, then titrated to maintain 2–3 soft stools per day.
Rifaximin 550 mg twice daily is used for secondary prophylaxis.
👉 Hepatorenal Syndrome
Management includes IV albumin (1 g/kg on day 1, then 20–40 g/day) plus a vasoconstrictor: terlipressin (1 mg IV every 6 hours, titrated as needed) or norepinephrine (0.5–3 mg/hour).
👉 Other Complications and Supportive Care
For pruritus, cholestyramine 4–16 g/day is first-line; naltrexone may be used for refractory cases.
Muscle cramps may be treated with taurine 1000 mg twice daily.
Sleep disturbance can be managed with hydroxyzine 25 mg nightly, but caution is warranted due to the risk of precipitating encephalopathy.
Statins are safe in compensated cirrhosis at low doses and may have beneficial effects on fibrosis and outcomes.
Referral for liver transplantation should be considered in patients with decompensation or HCC.
Emerging therapies such as L-ornithine L-aspartate for hepatic encephalopathy and long-term albumin for ascites are under investigation and not yet standard of care. TIPS is increasingly considered earlier in refractory ascites and for high-risk variceal bleeding.
🌟 All management should be individualized, with close monitoring for adverse effects and complications.
❤3
Role of albumin.pdf
1.5 MB
Role of albumin infusion in cirrhosis‑associated complications.
Clinical and Experimental Medicine (2024)
❤1
jama_tilg_2025_rv_250034_1761925736.90918.pdf
595.4 KB
Review: Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults.
JAMA 10 November 2025